MétaCan
Menu
Back to cohort
Record W2046182548 · doi:10.1007/s10227-005-0103-6

Safety and Efficacy of a Milk-derived Extract in the Treatment of Plaque Psoriasis:An Open-label Study

2005· article· en· W2046182548 on OpenAlexaff
Yves Poulin, Yves Pouliot, Éric Lamiot, N. Aattouri, Sylvain Gauthier

Bibliographic record

VenueJournal of Cutaneous Medicine and Surgery · 2005
Typearticle
Languageen
FieldImmunology and Microbiology
TopicPsoriasis: Treatment and Pathogenesis
Canadian institutionsUniversité LavalCentre de Recherche Dermatologique du Québec Métropolitain
Fundersnot available
KeywordsMedicinePsoriasisTolerabilityAdverse effectPlaque psoriasisOpen labelInternal medicineDermatology

Abstract

fetched live from OpenAlex

XP-828L is a nutraceutical compound obtained by the extraction of a growth factors-enriched protein fraction from bovine milk. XP-828L may improve psoriasis. An open-label study was performed to determine the efficacy, tolerability and safety of XP-828L in the treatment of plaque psoriasis. Eleven adult patients with chronic, stable plaque psoriasis on 2% or more of body surface area (BSA) received 5 g of oral XP-828L twice daily for 56 days. All 11 patients completed the 56 days of treatment. At day 28, 6 of the 11 patients showed a reduction in PASI score. At 56 days, seven subjects had a decrease in PASI score ranging from 9.5% to 81.3%. Eight (8) out of 11 patients agreed to participate in an additional 8-week extension treatment phase. Improvement of psoriasis was maintained during the extension period. No clinically significant adverse events or laboratory abnormalities occurred. XP-828L may improve psoriasis in patients with mild-to-moderate psoriasis. XP-828L est un composé nutraceutique obtenu par extraction d’une fraction protéique enrichie en facteurs de croissance à partir du lait bovin. XP-828L pourrait améliorer la condition des patients atteints de psoriasis. Une étude ouverte a été menée afin de déterminer l’efficacité, la tolérabilité et l’innocuité de XP-828L dans le traitement des plaques de psoriasis. Onze patients adultes présentant des plaques de psoriasis stables et chroniques sur 2% ou plus de la surface du corps on reçu par voie orale 5 g de XP-828L deux fois par jours pendant 56 jours. Les 11 patients ont tous complété 56 jours de traitement. Au 28e jour, 6 des 11 patients ont montré une réduction du PASI. Au 56e jour, sept patients ont montré une réduction du PASI allant de 9,5% à 81,3%. Huit (8) patients sur 11 ont accepté de participer à un traitement de 8 semaines supplémentaires. L’amélioration de la condition des patients s’est maintenue durant cette période additionnelle. Aucun événement indésirable marquant ou anormalité au niveau des tests de laboratoire n’ont été notés. XP-828L pourrait améliorer la condition des patients souffrant d’un psoriasis léger à modéré.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.011

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0030.001
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.049
GPT teacher head0.306
Teacher spread0.256 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations17
Published2005
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Cutaneous Medicine and SurgerySame topicPsoriasis: Treatment and PathogenesisFrench-language works237,207